Thoratec seeks broader indication for VAD (ventricular assist device) System
This article was originally published in Clinica
Executive Summary
Thoratec Laboratories says it has received a favourable initial response from the FDA in its efforts to gain approval to use its ventricular assist device (VAD) system for the reversal of late-stage heart failure. The company has filed a pre-PMA supplement, which allows it to maintain an informal dialogue with the agency prior to submitting a full PMA supplement application.
You may also be interested in...
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.